Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.350
-0.340 (-20.12%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Lexaria Bioscience Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Lexaria Bioscience stock has a target of 7.00, which predicts an increase of 418.52% from the current stock price of 1.35.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 24, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Lexaria Bioscience is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +418.52% | Jan 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +640.74% | Dec 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +640.74% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +640.74% | Jul 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +640.74% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
606.90K
from 464.28K
Increased by 30.72%
Revenue Next Year
800.19K
from 606.90K
Increased by 31.85%
EPS This Year
-0.60
from -0.47
EPS Next Year
-0.47
from -0.60
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 741,300 | 1.2M | 1.5M | ||
| Avg | 606,900 | 800,190 | 1.4M | ||
| Low | 474,320 | 392,000 | 1.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.7% | 102.2% | 84.1% | ||
| Avg | 30.7% | 31.8% | 78.8% | ||
| Low | 2.2% | -35.4% | 71.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.60 | -0.47 | -0.40 |
| Avg | -0.60 | -0.47 | -0.39 |
| Low | -0.59 | -0.46 | -0.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.